At the news
? NEUTRALIMPACT 3/10 6-K filed Mar 26, 2026 at 12:55 ET
Valneva announced its participation in the 26th World Vaccine Congress in Washington, DC, where it will present updates on its chikungunya vaccine IXCHIQ, including real-world evidence from a pilot vaccination campaign in Brazil involving over 12,000 individuals. The company will also engage in discussions on mosquito-borne diseases and meet with current and potential partners.
- Valneva will present chikungunya vaccine IXCHIQ Phase IV and real-world evidence data at the World Vaccine Congress on April 1, 2026.
- Over 12,000 people have been vaccinated in a pilot campaign in Brazil with IXCHIQ, conducted in partnership with Instituto Butantan.
- The data presented will support post-marketing commitments and evaluate the real-world effectiveness and safety of IXCHIQ.
- Valneva executives will participate in a panel discussion on mosquito-borne vaccines and outbreak response.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access